Ocular Therapeutix initiates travoprost implant trial

The first patient has been treated in a proof-of-concept clinical trial of a travoprost implant under study for the treatment of glaucoma, Ocular Therapeutix announced in a press release.

The travoprost product, OTX-TIC, is bioresorbable, delivered via intracameral injection and intended to reduce IOP in patients with glaucoma or ocular hypertension.

The phase 1 prospective, open-label, multicenter study is being conducted in the U.S. Safety, efficacy, durability and tolerability will be assessed.

The target duration of drug delivery for one sustained-release dose of OTX-TIC into the anterior chamber of the eye is 4 to 6 months, according to the release.

“OTX-TIC is designed to directly address compliance issues by delivering travoprost over the course of several months with a single implant,” Michael Goldstein, MD, chief medical officer of Ocular Therapeutix, said in the release.

The first patient has been treated in a proof-of-concept clinical trial of a travoprost implant under study for the treatment of glaucoma, Ocular Therapeutix announced in a press release.

The travoprost product, OTX-TIC, is bioresorbable, delivered via intracameral injection and intended to reduce IOP in patients with glaucoma or ocular hypertension.

The phase 1 prospective, open-label, multicenter study is being conducted in the U.S. Safety, efficacy, durability and tolerability will be assessed.

The target duration of drug delivery for one sustained-release dose of OTX-TIC into the anterior chamber of the eye is 4 to 6 months, according to the release.

“OTX-TIC is designed to directly address compliance issues by delivering travoprost over the course of several months with a single implant,” Michael Goldstein, MD, chief medical officer of Ocular Therapeutix, said in the release.